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C isplatin-based chemotherapy shows a survival advantage compared to carboplatin-based che-
motherapy for the treatment of advanced non-small cell 
lung cancer (NSCLC) [1-3].  However,  as high-volume 
hydration and a long infusion time are needed to avoid 
renal toxicity,  cisplatin-based chemotherapy has been 
difficult to administer in outpatient settings.  To address 
this problem,  the U.S.  National Comprehensive Cancer 
Network (NCCN) introduced a low-volume hydration 
method (short hydration) for cisplatin administration.  
In addition,  we conducted two prospective studies that 
successfully showed the feasibility of short-term 
low-volume orally administered hydration using a total 
of 2.5 L over a 4.5-h period and 1.7 over a 3-h period 
[4 , 5],  enabling the use of cisplatin in an outpatient set-
ting [6].
Nephrotoxicity is among the most important adverse 
events of cisplatin treatment [7],  and mannitol,  an 
osmotic diuretic,  is usually used for forced diuresis to 
reduce cisplatin-induced nephrotoxicity in the short-
term hydration method [8].  In an in vivo study using 
dogs,  intravenous mannitol infusion and massive 
hydration were shown to prevent renal toxicity [9].  
Furosemide,  a loop diuretic,  is also used for the pre-
vention of cisplatin-induced renal toxicity [8].  In 
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Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating 
advanced non-small cell lung cancer,  high-volume hydration and a long infusion time are necessary to avoid 
nephrotoxicity,  and cisplatin-based chemotherapy has been difficult to administer in outpatient settings.  A 
low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced,  but 
there are no clear conclusions regarding which agent should be used.  We describe our ongoing randomized 
phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis.  This study will clarify whether 
mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.
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another in vivo study,  renal function was assessed by the 
measurement of blood urea nitrogen (BUN),  and the 
estimated glomerular filtration rate (eGFR) was par-
tially protected in rats given furosemide [10].
Some reports comparing the use of mannitol with 
that of furosemide have been published,  but there have 
been no clear conclusions regarding which agent should 
be used in cisplatin-based chemotherapy [11 , 12].  To 
clarify which diuresis agent (i.e.,  mannitol or furose-
mide) is more suitable for cisplatin-based chemother-
apy using the short-term hydration method,  we have 
designed a study to evaluate the efficacy of these 2 drugs 
in patients with advanced NSCLC.  We present here the 
design,  methods and protocol of this investigation,  
which has been named the OLCSG1406 study.
Methods and Design
Objective. This study was designed to evaluate 
the efficacies of mannitol and furosemide for forced 
diuresis in cisplatin-based chemotherapy with short-
term hydration for advanced NSCLC.
Study design. The study was designed as a two-
arm,  prospective,  randomized single-center phase II 
trial.  Fig. 1 provides an overview of the study design.  
Written informed consent must be obtained from the 
patients before any screening or inclusion procedure.  
This study will be conducted in compliance with the 
principles of the Declaration of Helsinki,  and the pro-
tocol was approved by the Institutional Review Board of 
Okayama University (approval no. m04009) and was 
registered with the UMIN Clinical Trials Registry with 
the registration number UMIN000015293.
Endpoints. The study’s primary endpoint is the 
rate of patients with serum creatinine elevation,  defined 
as grade 1 or higher by the Common Terminology 
Criteria for Adverse Events (CTCAE),  ver. 4.0,  during 
the first cycle of cisplatin-based chemotherapy.  We will 
record renal toxicity during all of the chemotherapy 
cycles.  Secondary outcome measures are the objective 
response rate,  toxicity,  overall survival,  and progres-
sion-free survival.  Regarding the patients’ responses to 
the chemotherapy with either agent,  the Response 
Evaluation Criteria in Solid Tumors (RECIST; ver. 1.1) 
will be applied.
Eligibility criteria. All patients who meet the 
main inclusion and exclusion criteria will be invited for 
screening.  The main inclusion and exclusion criteria are 
listed in Table 1.
Randomization. After the eligibility criteria are 
confirmed to have been met for a patient,  his or her 
registration is performed by fax or e-mail.  The minimi-
zation method is employed to assign patients randomly 
to either the furosemide arm or the mannitol arm,  
using performance status (0 or 1) and sex as adjustment 
factors.
Intervention. The treatment schedule is designed 
as shown in Table 2.  Cisplatin will be diluted in 500 ml 
of normal saline solution and administered over a 1-h 
period.  Magnesium sulfate,  the key agent to prevent 
renal toxicity [13],  will be supplemented at 4 mEq both 
before and after each cisplatin administration.  In arm 
A,  furosemide will be infused just after cisplatin 
administration.  In arm B,  mannitol will be infused just 
before cisplatin administration.  A total of 1.7 L for 
hydration will be administered over a 3-h period.  
Patients will be strongly advised to drink 1.5 L water on 
day 1 and 1 L on each of days 2 and 3 to avoid dehydra-
tion,  which may potentially lead to renal failure [14].  
This treatment will be repeated every 3 or 4 weeks for 4 
to 6 cycles unless disease progression or unacceptable 
toxicity is observed or the patient refuses further treat-
ment.  Maintenance therapy with pemetrexed or beva-
cizumab is accepted after four cycles of cisplatin.  All of 
the patients will receive the first cycle in an inpatient 
setting for a precise evaluation of the therapy’s safety,  
and subsequent cycles will be given in an outpatient 
setting if possible.
This study will be conducted in 2 steps.  Step 1 will 
be performed primarily to evaluate the tolerability of the 
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[ Key Inclusion Criteria ]
・Pathologically proven non-small cell lung cancer 
・Stage IV, incurable stage III or postoperative recurrence
・Combination chemotherapy using cisplatin and third-generation cytotoxic agents
・Aged 20 to 75 years
・ECOG PS of 0 to 1
・Appropriate renal function
(serum Crelevels within reference range and Ccr more than 60 mL/min)
Randomization
arm A
furosemide 20 mg iv
arm B
mannitol 30 g div
Fig. 1　 Overview of the study design.
forced diuresis in short-term hydration chemotherapy.  
In this step,  at least 6 patients will receive treatment in 
each arm.  Step 2 will subsequently be performed if 
grade 1 or higher serum creatinine elevation is 
observed in more than 2 patients.  All of the adverse 
events will be defined according to the CTCAE,  ver. 4.0.  
For the evaluation of creatinine toxicity,  2 types of 
grading systems are available; we will use the one based 
on the institutional upper limit of the normal range 
(ULN) for serum creatinine as described [4 , 5].  If grade 
3 or 4 serum creatinine elevation occurs,  the protocol 
treatment will be stopped and clinically available renal 
supportive care will be given.
Follow-up. All of the randomized patients will be 
followed-up for at least 1 year after the study’s patient 
accrual is completed.  General physical findings,  labo-
ratory data (including renal function),  tumor markers 
(carcinoembryonic antigen [CEA],  cytokeratin 19 frag-
ment [CYFRA],  sialyl LeX-i antigen [SLX],  squamous 
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Table 1　 Eligibility criteria of the OLCSG1406 Study
Inclusion criteria:
(1) Age 20-75 years
(2) Eastern Cooperative Oncology Group (ECOG) performance 
status 0-1
(3) Pathologically proven non-small cell lung cancer
(4) Stage IV, incurable stage III or postoperative recurrence dis-
ease
(5) Combination chemotherapy with cisplatin and third-generation 
anticancer drug (including triplet therapy using bevacizumab)
(6) Presence of any measurable or immeasurable lesions 
(RECIST v1.1)
(7) No prior systemic cytotoxic chemotherapy except for post-op-
erative adjuvant therapy >6 months prior to registration
(8) More than 1 week after palliative radiation therapy for meta-
static lesions other than extremity bone metastasis
(9) More than 1 week after the drainage of pleural eﬀusion, car-
diac eﬀusion, and ascites
(10) Adequate organ function as deﬁned by the following: leuko-
cyte count >3,000/µL, absolute neutrophil count >1,500/µL, 
platelet count >150,000/µL, hemoglobin level >9 g/dL, total 
bilirubin level <1.5 mg/dL, aspartate aminotransferase and 
alanine transaminase levels <2.5-fold the institutional upper 
limit of the normal range (ULN), creatinine within the ULN and 
creatinine clearance >60 mL/min, arterial oxygen partial pres-
sure >60 mmHg or saturation of pulse oximetry oxygen 
>90% in room air
Exclusion criteria:
(1) Cisplatin level <75 mg/m2 on day 1
(2) Patients with active co-morbidities, including severe heart 
disease, cerebrovascular diseases, gastric ulcers, severe 
infections, uncontrollable diabetes, psychological diseases, 
and hearing loss
(3) Active interstitial lung diseases
(4) Symptomatic brain metastasis
(5) Uncontrolled third-space ﬂuid retention
(6) History of other malignancies within the past 3 years
(7) Pregnant or breast-feeding women
(8) Regular use of oral diuresis
(9) Incapable of drinking 1 L per day
(10) Treatment with the split schedule of the cisplatin or cispla-
tin-etoposide regimen requiring drip infusion even on days 2 
and 3
Table 2　 Schedule of short-term low-volume hydration in cispla-
tin-based chemotherapy on day 1
Chemotherapeutic and Hydration Agents and Their Dosage
Antiemetic premedication:  Normal saline solution with palonosetron 
0.75 mg,  dexamethasone 9.9 mg,  mag-
nesium sulfate 4 mEq,  100 mL (15 min)
Cytotoxic agents:  Normal saline solutiona with an anticancer agent 
that would be combined with cisplatin,  500 mL 
(1 h)
Diuresis: (Arm B),  20% mannitol,  150 mL (15 min)
Cisplatin:  Normal saline solution with cisplatin >75 mg/m2 
500b mL (1 h)
Diuresis: (Arm A),  furosemide 20 mg,  2 mL (bolus)
Hydration:  1/4 normal saline solution with magnesium sulfate 
4 mEq,  KCl 4 mEq,  200 mL (30 min)
Total: 1,700 mL (3 h)
The venous line was maintained using 250 mL od normal saline 
throughout the infusion.  The dose schedules for cisplatin and anti-
cancer agents combined with cisplatin were based on the latest 
National Comprehensive Cancer Center guidelines.  In the case of 
triplet chemotherapy with bevacizumab,  it was diluted in 100 mL od 
normal saline and administered after the completion of post-hydra-
tion.
a Vinorelbine,  pemetrexed,  and gemcitabine were diluted in 50,  
100,  and 100 mL of normal saline (5,  10,  and 30 min),  respectively.  
In addition,  250 mL od normal saline solution were administered.
b A total of 500 mL with cisplatin and normal saline solution.
cell carcinoma-related antigen [SCC]),  and chest X-ray 
results will be obtained monthly during the first year 
and every 3 months after the first year until the patients 
complete or stop cisplatin-based chemotherapy,  or until 
disease progression.  Enhanced chest and abdominal 
computed tomography or brain magnetic resonance 
imaging will be evaluated as necessary.
Statistical consideration. This study will evaluate 
the feasibility of the two forced diuresis methods in cis-
platin-based chemotherapy with short-term hydration 
for advanced NSCLC.  The primary endpoint is the rate 
of patients without an elevation in serum creatinine 
levels,  defined as grade 1 or higher during the first 
cycle,  according to CTCAE,  ver. 4.0.
In previous studies of mannitol,  15-27% of the 
patients developed grade 1 or higher creatinine toxicity 
[4 , 15 , 16].  In studies of furosemide,  18-52% of the 
patients developed grade 1 or higher creatinine toxicity 
[8 , 17].  Thus,  we estimated that the probability of 
grade 1 or higher creatinine toxicity was 35% with 
furosemide and 20% with mannitol.  The target sample 
size to select the arm with the lower probability of renal 
toxicity,  with an accuracy of 90%,  is 30 cases in each 
arm according to Simon’s selection theory.  With an 
assumed 10% dropout rate,  66 patients are needed in 
total.
Overall survival will be defined as the interval 
between the date of enrollment in this study and death 
or the last follow-up visit.  Progression-free survival will 
be defined as the interval between the date of enroll-
ment in this study and progressive disease (RECIST PD) 
or death.  The survival distribution will be estimated 
using the Kaplan-Meier method.  All of the statistical 
analyses will be conducted using STATA/SE ver. 14.0 
software (College Station,  TX,  USA).
Discussion
To date,  cisplatin-based chemotherapy is the stan-
dard therapy for advanced NSCLC.  We reported the 
safety of short-term low-volume hydration [5],  but few 
prospective randomized studies regarding the appropri-
ate forced diuresis have been conducted.  Mannitol,  an 
osmotic diuretic,  has been used worldwide for forced 
diuresis,  but it has the potential side effect of vascular 
pain,  which impairs patients’ quality of life.  This study 
will clarify whether the use of mannitol or that of furo-
semide is more feasible for forced diuresis in moder-
ate-dose cisplatin-based chemotherapy with short-term 
hydration.  We hope this study will provide novel data 
that can assure a more feasible method of moder-
ate-dose cisplatin-based chemotherapy with short-term 
hydration for advanced NSCLC.
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